Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

JAML is a novel immunotherapy target for tissue-resident memory T cells

ABSTRACT: JAML is a novel immunotherapy target for tissue-resident memory T cells

PROVIDER: PRJNA767854 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16152126_1.fastq.gz	Fastqsanger.gz
	SRR16152126_2.fastq.gz	Fastqsanger.gz
	SRR16152127_1.fastq.gz	Fastqsanger.gz
	SRR16152127_2.fastq.gz	Fastqsanger.gz
	SRR16150338_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 52

Similar Datasets

JAML is a novel immunotherapy target for tissue-resident memory T cells [scRNA-seq]

Project description:JAML is a novel immunotherapy target for tissue-resident memory T cells [scRNA-seq]

| PRJNA767856 | ENA

JAML is a novel immunotherapy target for tissue-resident memory T cells [bulk RNA-seq]

Project description:JAML is a novel immunotherapy target for tissue-resident memory T cells [bulk RNA-seq]

| PRJNA767935 | ENA

Tumor-resident memory-like CD8 T cells represent an essential cellular target for cancer immunotherapy

Project description:Tumor-resident memory-like CD8 T cells represent an essential cellular target for cancer immunotherapy

| PRJNA472005 | ENA

JAML is a novel immunotherapy target for tissue-resident memory T cells [scRNA-seq]

Project description:Tumor-infiltrating CD8+ T cells express high levels of the co-stimulatory molecule JAML, which can be exploited for cancer immunotherapy.

2023-08-08 | GSE185161 | GEO

JAML is a novel immunotherapy target for tissue-resident memory T cells [bulk RNA-seq]

Project description:Tumor-infiltrating CD8+ T cells express high levels of the co-stimulatory molecule JAML, which can be exploited for cancer immunotherapy.

2023-08-08 | GSE185160 | GEO

CD8 Tissue Resident Memory (TRM) induction

Project description:CD8 Tissue Resident Memory (TRM) induction

| PRJNA1036221 | ENA

Ex Vivo Expansion and Hydrogel-Mediated In Vivo Delivery of Tissue Resident Memory T Cells for Immunotherapy

Project description:Tissue-resident memory (TRM) T cells preferentially reside in peripheral tissues, serving as key players in tumor immunity and immunotherapy. Currently, the lack of effective approaches for expanding TRM cells and delivering these cells in vivo hinder the exploration of TRM cell-mediated cancer immunotherapy. Here, we report a nanoparticle artificial antigen-presenting cell (nano-aAPC) ex vivo expansion approach and an in vivo delivery system for TRM cells. Using the nano-aAPC platform, we expanded functional antigen-specific murine and human TRM-like CD8+ T cells ex vivo. We also developed an injectable macroporous hyaluronic acid (HA) hydrogel for delivery of TRM-like cells. TRM-like cells delivered in the optimized HA hydrogel trigger robust local and systemic antitumor immunity and show synergistic effect with anti-PD1 treatment. Our findings suggest that nano-aAPC-induced TRM-like cells, coupled with a hydrogel delivery system, offer an efficient way to advance the understanding of TRM cells-mediated cancer therapy.

2024-06-04 | GSE267822 | GEO

Genome wide transcriptome analysis of skin harboring tissue-resident memory CD8+ T cells

Project description:Comparison of the transcriptional profiles of full-thickness murine skin harboring tissue resident memory T cells exposed to specific or control trigger Expression profiling by high throughput sequencing

2014-09-11 | E-GEOD-60599 | biostudies-arrayexpress

Tissue-resident Memory and Circulating T cells are Early Responders to Pre-surgical Cancer Immunotherapy

Project description:Tissue-resident Memory and Circulating T cells are Early Responders to Pre-surgical Cancer Immunotherapy

| PRJNA827834 | ENA

Tumor-resident memory-like CD8 T cells represent an essential cellular target for cancer immunotherapy

Project description:Persistent exposure to high levels of antigen results in the progressive exhaustion of T cells and has been thought to preclude the formation of memory. In contrast to the latter assumption, we show here that tumor-specific CD8 T cells residing in the tumor microenvironment include a Tcf1 expressing sub population that has key characteristics of central memory cells, lack an effector cell signature but display hallmarks of exhausted T cells, including the expression co-inhibitory receptors such as PD1. Similar memory-like cells are identified in melanoma patients. Preclinical mouse models reveal that the expansion of tumor-specific CD8 T cells, the production of terminally differentiated exhausted CD8 T cells and sustained tumor control in response to therapeutic vaccination or immune checkpoint blockade critically depends on the presence of these memory-like CD8 T cells. Tumor immune responses thus harbor tumor resident memory-like CD8 T cell populations, which can be therapeutically targeted to improve immune control of cancer.

2019-01-10 | GSE114631 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data